National patterns and predictors of β-blocker use in patients with coronary artery disease

Archives of Internal Medicine

Volumn 158, Issue 17, 1998, Pages 1901-1906

  Wang, Thomas J ^b   Stafford, Randall S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; CONSULTATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AMBULATORY CARE; ANALYSIS OF VARIANCE; CORONARY DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OFFICE VISITS; SOCIAL CLASS; UNITED STATES;

EID: 0032575873     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.17.1901     Document Type: Article

References (55)

1. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. JAMA. 1988; 259:1976-1982.
2. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
3. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707-1714.
4. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. Circulation. 1994; 90:762-768.
5. Lau J, Antman EM, Jimenez-Silva J, Kupelnik B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
6. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988;319:152-157.
7. Goldman L. Cost-effectiveness perspectives in coronary heart disease. Am Heart J. 1990;119:733-740.
8. Pashos CL, Normand ST, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol. 1994;23:1023-1030.
9. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol. 1995;25:1327-1332.
10. Montague TJ, Ikuta RM, Wong RY, Bay KS, Teo KK, Davies NJ. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol. 1991; 68:843-847.
11. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992;93:605-610.
12. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA. 1995;273:1509-1514.
13. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol. 1995;26:1432-1436.
14. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-121.
15. National Center for Health Statistics. Public Use Data Tape Documentation: 1980 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Hearth Statistics, US Public Health Service; 1982.
16. National Center for Health Statistics. Public Use Data Tape Documentation: 1981 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1984.
17. National Center for Health Statistics. Public Use Data Tape Documentation: 1985 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1987.
18. National Center for Health Statistics. Public Use Data Tape Documentation: 1989 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1992.
19. National Center for Health Statistics. Public Use Data Tape Documentation: 1990 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1992.
20. National Center for Health Statistics. Public Use Data Tape Documentation: 1991 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1993.
21. National Center for Health Statistics. Public Use Data Tape Documentation: 1992 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1994.
22. National Center for Health Statistics. Public Use Data Tape Documentation: 1993 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1995.
23. National Center for Health Statistics. Public Use Data Tape Documentation: 1994 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1995.
24. National Center for Health Statistics. Public Use Data Tape Documentation: 1995 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1997.
25. National Center for Health Statistics. Public Use Data Tape Documentation: 1996 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1997.
26. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. β-Blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA 1989;261:2087-2094.
27. Potthoff RF, Woodbury MA, Manton KG. "Equivalent sample size" and "equivalent degrees of freedom" refinements for inference using survey weights under superpopulation models. J Am Stat Assoc. 1992;87:383-396.
28. Pagley PR, Yarzebski J, Goldberg R, et al. Gender differences in the treatment of patients with acute myocardial infarction. Arch Intern Med. 1993;153:625-629.
29. Kennedy HL, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol. 1995;26:547-552.
30. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta-blocker use in community hospital patients discharged after myocardial infarction. J Gen Intern Med. 1994;9:599-605.
31. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259-2263.
32. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland interuniversity Nifedipine/Metoprolol Trial (HINT). Am J Cardiol. 1987;60:18A-25A.
33. Kaplan JR, Manuck SB. Antiatherogenic effects of β-adrenergic blocking agents: theoretical, experimental, and epidemiologic considerations. Am Heart J. 1994; 128:1316-1328.
34. Wikstrand J, Berglund G, Tuomilehto J. Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Circulation. 1991;84: 93-100.
35. Goldstein S. β-Blockers in hypertensive and coronary heart disease. Arch Intern Med. 1996;156:1267-1276.
36. Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. Arch Intern Med. 1991; 151:1769-1776.
37. Burns JF. β-Blockers, dyslipidemia, and coronary artery disease. Arch Intern Med. 1993;153:2085-2092.
38. Dahlof C, Dimenas E, Kendall M, Wiklund I. Quality of life in cardiovascular diseases. Circulation. 1991;84(suppl VI):VI-108-VI-118.
39. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11: 43-50.
40. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? BMJ. 1980;280:976-978.
41. Waggstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
42. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
43. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
44. Bright RA, Everitt DE. β-Blockers and depression. JAMA. 1992;267:1783-1787.
45. Smith SC, Gilpin E, Ahnve S, et al. Outlook after acute myocardial infarction in the very elderly compared with that in patients aged 65 to 75 years. J Am Coll Cardiol. 1990;16:784-792.
46. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med. 1995;333: 565-572.
47. Stafford RS, Blumenthal D, Pasternak R. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol. 1997;29:139-146.
48. Stafford RS, Singer D. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
49. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.
50. Carlisle DM, Leake BD, Shapiro MF. Racial and ethnic differences in the use of invasive cardiac procedures among cardiac patients in Los Angeles County, 1986 through 1988. Am J Public Health. 1995;85:352-356.
51. Giles WH, Anda RF, Casper ML, Escobedo LG, Taylor HA. Race and sex differences in rates of invasive cardiac procedures in US hospitals. Arch Intern Med. 1995;155:318-324.
52. Peterson ED, Wright SM, Daley J, Thibault GE. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA. 1994;271:1175-1180.
53. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial Differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med. 1993;329:621-627.
54. National High Blood Pressure Education Program. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
55. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive therapies. JAMA. 1995;274:620-625.